조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2023년10월
Immunoassay Market – Global Forecast to 2028
면역측정 (Immunoassay) 시장 : 제품(시약 및 키트, 분석기), 기술(ELISA, CLIA, 신속 검사), 시료(혈액, 타액, 소변), 용도(감염, 내분비학), 최종 사용자(병원 및 클리닉, 혈액 은행), 지역별 – 2028년까지의 세계 예측
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) & Region – Global Forecast to 2028
| 페이지 수 | 382 |
| 도표 수 | 361 |
| 구성 | 영문조사보고서 |
| 가격 |
Report Overview
The global immunoassay market is valued at an estimated USD 35.0 billion in 2023 and is projected to reach USD 46.7 billion by 2028, at a CAGR of 5.9% during the forecast period. Market growth is driven by factors such as the rising prevalence of chronic and infectious diseases, innovations in the systems and technologies, supportive government policies and initiatives, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
“The reagents & kits to register the largest share of the immunoassay market, by product.”
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the repetitive use of reagents & kits for various diagnostic procedures coupled with the increase in the volume of immunoassay-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.
“Chemiluminescence Immunoassay segment to grow at a considerable rate among technology during the forecast period.”
The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. CLIA tests help efficiently diagnose various chronic and infectious diseases compared to other techniques such as ELISA and radioimmunoassays, owing to benefits such as sensitivity, wide dynamic range, better speed, reduced interference, and high specificity.
“Infectious diseases segment accounted for the largest share in the immunoassay market, by application.”
The global immunoassay market is segmented into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring and testing, newborn screening, and other applications. The application segment of infectious diseases accounted for a considerable share in 2022, primarily due to the rapid diagnosis of infectious diseases coupled with the increasing incidence of diseases such as HIV/AIDS, malaria, hepatitis, and influenza, among others.
“Asia Pacific: The fastest-growing region in the immunoassay market.”
The global immunoassay market is segmented into five regions – North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the immunoassay market. The high growth in the region is due to the presence of a large target population, and rising prevalence of chronic disorders in Asian countries.
The break-up of the profile of primary participants in the immunoassay market:
• By Company Type: Tier 1 – 28%, Tier 2 – 41%, and Tier 3 – 31%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 38%, Europe – 27%, Asia Pacific – 18%, Latin America – 6% and Middle East & Africa – 11%,
The key players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., LTD. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (India), and Maccura Biotechnology Co., Ltd. (China).
Research Coverage:
This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals and clinics, research & academic laboratories, blood banks, pharmaceutical and biotechnology companies & CROs, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the immunoassay market. This report covers the competitive analysis of upcoming startups in the immunoassay market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, in systems and technologies, growth in biotechnology and biopharmaceutical industries, increasing adoption of immunoassay-based POC testing and rapid testing, supportive government policies, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavourable reimbursement scenario, and financial hurdles faced by physicians) influencing the growth of the immunoassay market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the immunoassay market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US)among others in the immunoassay market strategies.
Table of Contents
1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 INCLUSIONS & EXCLUSIONS 41
1.4 MARKET SCOPE 42
1.4.1 MARKETS COVERED 42
FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION 42
1.4.2 REGIONS COVERED 43
1.4.3 YEARS CONSIDERED 43
1.4.4 CURRENCY CONSIDERED 44
1.5 STAKEHOLDERS 44
1.6 SUMMARY OF CHANGES 44
1.6.1 IMPACT OF RECESSION: IMMUNOASSAY MARKET 45
2 RESEARCH METHODOLOGY 46
2.1 RESEARCH DATA 46
FIGURE 2 RESEARCH DESIGN 46
2.1.1 SECONDARY RESEARCH 47
2.1.1.1 Key data from secondary sources 48
2.1.2 PRIMARY RESEARCH 48
2.1.2.1 Primary sources 48
2.1.2.2 Key data from primary sources 49
2.1.2.3 Key industry insights 50
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 51
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 51
2.2 MARKET SIZE ESTIMATION 52
FIGURE 5 REVENUE SHARE ANALYSIS 52
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 53
FIGURE 7 TOP-DOWN APPROACH 54
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 55
FIGURE 8 DATA TRIANGULATION METHODOLOGY 55
2.4 MARKET SHARE ANALYSIS 56
2.5 STUDY ASSUMPTIONS 56
2.5.1 MARKET ASSUMPTIONS 56
2.5.2 GROWTH RATE ASSUMPTIONS 56
2.6 RESEARCH LIMITATIONS 57
2.6.1 METHODOLOGY-RELATED LIMITATIONS 57
2.6.2 SCOPE-RELATED LIMITATIONS 57
2.7 RISK ASSESSMENT 57
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET 57
2.8 IMPACT OF RECESSION ON IMMUNOASSAY MARKET 57
3 EXECUTIVE SUMMARY 59
FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 59
FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 60
FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION) 61
FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION) 62
FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 63
FIGURE 14 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET 64
4 PREMIUM INSIGHTS 65
4.1 IMMUNOASSAY MARKET OVERVIEW 65
FIGURE 15 RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 65
4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY (2022) 66
FIGURE 16 REAGENTS & KITS AND US DOMINATED NORTH AMERICAN IMMUNOASSAY MARKET IN 2022 66
4.3 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET, 2023–2028 67
FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD 67
4.4 REGIONAL MIX: IMMUNOASSAY MARKET, 2021–2028 68
FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 68
4.5 DEVELOPED VS. EMERGING ECONOMIES: IMMUNOASSAY MARKET, 2023–2028 69
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing incidence of chronic and infectious diseases 71
FIGURE 21 INCREASING INCIDENCES OF DIABETES (IN MILLION) 71
5.2.1.1.1 Growing use of immunoassays in oncology 72
TABLE 2 GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020 72
TABLE 3 GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020 73
5.2.1.1.2 Increasing use of immunoassays in diagnostic applications 73
TABLE 4 TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING 73
5.2.1.1.3 Growing geriatric population 74
FIGURE 22 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION) 74
5.2.1.2 Increasing need for blood donations 75
5.2.1.3 Growth in biotechnology & biopharmaceutical industries 75
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing 76
5.2.1.5 Supportive government regulatory policies and initiatives 77
5.2.1.6 Increased drug abuse and use of cannabis 77
5.2.2 RESTRAINTS 78
5.2.2.1 Stringent approval criteria for immunoassay instruments and consumables 78
5.2.2.2 Technical problems in immunoassay kits 78
5.2.3 OPPORTUNITIES 79
5.2.3.1 Increasing growth opportunities in emerging economies 79
5.2.3.2 Importance of companion diagnostics 80
TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018–2022 80
5.2.3.3 Development of condition-specific biomarkers and tests 81
TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS, 2019–2023 81
5.2.3.4 Integration of microfluidics in immunoassays 82
TABLE 7 LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS 82
5.2.3.5 Improved immunoassay diagnostic technologies 83
5.2.4 CHALLENGES 83
5.2.4.1 Design challenges, complexities, and low quality of antibodies 83
5.2.4.2 Dearth of skilled professionals 83
5.2.4.3 Unfavorable reimbursement scenario 84
5.3 REGULATORY ANALYSIS 84
5.3.1 NORTH AMERICA 84
5.3.1.1 US 84
TABLE 8 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 84
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES 85
5.3.1.2 Canada 86
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES 86
5.3.2 EUROPE 86
TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES 86
5.3.2.1 Russia 87
TABLE 10 RUSSIA: CLASSIFICATION OF IVD DEVICES 87
5.3.3 ASIA PACIFIC 88
5.3.3.1 Japan 88
FIGURE 25 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 88
TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS 89
TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.3.3.2 China 89
TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.3.3.3 India 90
FIGURE 26 INDIA: REGULATORY PROCESS FOR IVD DEVICES 90
5.3.3.4 Indonesia 91
TABLE 14 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 91
5.3.3.5 South Korea 91
TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.3.4 LATIN AMERICA 92
5.3.4.1 Mexico 92
FIGURE 27 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 92
TABLE 16 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 92
5.3.4.2 Brazil 93
FIGURE 28 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 93
5.3.5 MIDDLE EAST 93
5.3.5.1 Saudi Arabia 94
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 94
5.3.6 AFRICA 94
5.4 TECHNOLOGY ANALYSIS 94
TABLE 18 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 95
TABLE 19 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET 95
5.5 TRADE ANALYSIS 96
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS 96
TABLE 20 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 96
TABLE 21 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 96
5.6 PATENT ANALYSIS 97
5.7 VALUE CHAIN ANALYSIS 98
FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 98
5.8 SUPPLY CHAIN ANALYSIS 99
FIGURE 30 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES 99
5.9 ECOSYSTEM/MARKET MAP 100
FIGURE 31 ECOSYSTEM/MARKET MAP: IMMUNOASSAY MARKET 100
5.9.1 ROLE IN ECOSYSTEM 100
5.9.2 KEY PLAYERS IN IMMUNOASSAY MARKET 101
5.10 PORTER’S FIVE FORCES ANALYSIS 102
TABLE 22 PORTER’S FIVE FORCES 102
5.10.1 INTENSITY OF COMPETITIVE RIVALRY 102
5.10.2 BARGAINING POWER OF SUPPLIERS 102
5.10.3 BARGAINING POWER OF BUYERS 102
5.10.4 THREAT OF SUBSTITUTES 102
5.10.5 THREAT FROM NEW ENTRANTS 103
5.11 KEY CONFERENCES & EVENTS IN 2023–2024 103
TABLE 23 KEY CONFERENCES & EVENTS IN 2023–2024 103
5.12 PRICING ANALYSIS 104
TABLE 24 PRICE RANGE FOR IMMUNOASSAY PRODUCTS 104
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 105
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 105
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 105
TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 105
5.13.2 BUYING CRITERIA 106
FIGURE 33 KEY BUYING CRITERIA FOR TOP END USERS 106
TABLE 26 KEY BUYING CRITERIA, BY TOP END USER 106
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 107
6 IMMUNOASSAY MARKET, BY PRODUCT 108
6.1 INTRODUCTION 109
TABLE 27 IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 109
6.2 REAGENTS & KITS 109
TABLE 28 KEY REAGENTS & KITS AVAILABLE 110
TABLE 29 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 30 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 111
6.2.1 ELISA REAGENTS & KITS 112
6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment 112
TABLE 31 ELISA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 113
6.2.2 RAPID TEST REAGENTS & KITS 113
6.2.2.1 High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment 113
TABLE 32 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 114
6.2.3 ELISPOT REAGENTS & KITS 114
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive segment 114
TABLE 33 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 115
6.2.4 CLIA REAGENTS & KITS 115
6.2.4.1 Better diagnosis and higher specificity to drive segment 115
TABLE 34 CLIA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
6.2.5 IFA REAGENTS & KITS 116
6.2.5.1 Better adaptability in clinical diagnostics and medicine to drive segment 116
TABLE 35 IFA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
6.2.6 WESTERN BLOT REAGENTS & KITS 117
6.2.6.1 Western blotting reagents & kits to be considered gold standard for COVID-19 test result validation 117
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
6.2.7 OTHER REAGENTS & KITS 118
TABLE 37 OTHER REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
6.3 ANALYZERS 119
TABLE 38 KEY ANALYZERS AVAILABLE 120
TABLE 39 IMMUNOASSAY MARKET FOR ANALYZERS, BY REGION, 2021–2028 (USD MILLION) 121
6.3.1 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE 121
TABLE 40 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 122
6.3.1.1 Open-ended systems 122
6.3.1.1.1 Better flexibility and wider availability to drive segment 122
TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 122
6.3.1.2 Closed-ended systems 123
6.3.1.2.1 Higher precision and better automation to drive segment 123
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 123
6.3.2 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE 123
TABLE 43 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 123
6.3.2.1 Rental purchase 124
6.3.2.1.1 Increased convenience and lack of liability to drive segment 124
TABLE 44 RENTAL PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION) 124
6.3.2.2 Outright purchase 124
6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market 124
TABLE 45 OUTRIGHT PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION) 125
7 IMMUNOASSAY MARKET, BY TECHNOLOGY 126
7.1 INTRODUCTION 127
TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 127
7.2 ELISA 127
7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET 127
TABLE 47 KEY ELISA TECHNOLOGIES AVAILABLE 128
TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION) 129
7.3 CLIA 129
7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET 129
TABLE 49 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2021–2028 (USD MILLION) 130
7.4 IFA 130
7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES 130
TABLE 50 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2021–2028 (USD MILLION) 131
7.5 RAPID TESTS 131
7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE MARKET 131
TABLE 51 KEY RAPID TESTS AVAILABLE 131
TABLE 52 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION) 132
7.6 WESTERN BLOTTING 132
7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET 132
TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE 133
TABLE 54 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION) 133
7.7 ELISPOT 133
7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET 133
TABLE 55 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2021–2028 (USD MILLION) 134
7.8 OTHER TECHNOLOGIES 134
TABLE 56 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 135
8 IMMUNOASSAY MARKET, BY SPECIMEN 136
8.1 INTRODUCTION 137
TABLE 57 IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 137
8.2 BLOOD 137
8.2.1 HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET 137
TABLE 58 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION) 138
8.3 SALIVA 139
8.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET 139
TABLE 59 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION) 139
8.4 URINE 139
8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET 139
TABLE 60 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 140
8.5 OTHER SPECIMENS 140
TABLE 61 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2021–2028 (USD MILLION) 141
9 IMMUNOASSAY MARKET, BY APPLICATION 142
9.1 INTRODUCTION 143
TABLE 62 IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
9.2 INFECTIOUS DISEASES 144
9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET 144
TABLE 63 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 144
9.3 ENDOCRINOLOGY 145
9.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET 145
TABLE 64 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 145
9.4 CARDIOLOGY 146
9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 146
TABLE 65 KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS 146
TABLE 66 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 147
9.5 AUTOIMMUNE DISORDERS 147
9.5.1 HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 147
TABLE 67 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION) 148
9.6 ALLERGY DIAGNOSTICS 148
9.6.1 GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET 148
TABLE 68 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 149
9.7 ONCOLOGY 149
9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO DRIVE MARKET 149
TABLE 69 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION) 150
TABLE 70 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 150
9.8 BONE & MINERAL DISORDERS 151
9.8.1 INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET 151
TABLE 71 KEY PRODUCTS FOR BONE & MINERAL DISORDERS 151
TABLE 72 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 152
9.9 DRUG MONITORING AND TESTING 152
9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 152
TABLE 73 KEY PRODUCTS FOR DRUG MONITORING 153
TABLE 74 KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING 153
TABLE 75 IMMUNOASSAY MARKET FOR DRUG MONITORING AND TESTING, BY REGION, 2021–2028 (USD MILLION) 154
9.10 BLOOD SCREENING 154
9.10.1 RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET 154
TABLE 76 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION) 155
9.11 NEWBORN SCREENING 155
9.11.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET 155
TABLE 77 KEY PRODUCTS FOR NEWBORN SCREENING 155
TABLE 78 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION) 156
9.12 OTHER APPLICATIONS 156
TABLE 79 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 157
10 IMMUNOASSAY MARKET, BY END USER 158
10.1 INTRODUCTION 159
TABLE 80 IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 159
10.2 HOSPITALS & CLINICS 159
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET 159
TABLE 81 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 161
10.3 CLINICAL LABORATORIES 161
10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET 161
TABLE 82 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 162
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 162
10.4.1 GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET 162
TABLE 83 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 163
10.5 HOME CARE SETTINGS 164
10.5.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET 164
TABLE 84 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION) 164
10.6 BLOOD BANKS 164
10.6.1 RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET 164
TABLE 85 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION) 165
10.7 RESEARCH & ACADEMIC LABORATORIES 165
10.7.1 RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET 165
TABLE 86 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 166
11 IMMUNOASSAY MARKET, BY REGION 167
11.1 INTRODUCTION 168
TABLE 87 IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 168
11.2 NORTH AMERICA 168
FIGURE 34 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 169
TABLE 88 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 89 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 170
TABLE 90 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 91 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 92 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 172
TABLE 93 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 173
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 96 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 174
11.2.1 NORTH AMERICA: RECESSION IMPACT 174
11.2.2 US 175
11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market 175
TABLE 97 US: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176
TABLE 98 US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 99 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 100 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 177
TABLE 101 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178
TABLE 102 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 178
TABLE 103 US: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 104 US: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 180
11.2.3 CANADA 180
11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market 180
TABLE 105 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 181
TABLE 106 CANADA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 107 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 108 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 183
TABLE 109 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183
TABLE 110 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 184
TABLE 111 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 112 CANADA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 185
11.3 EUROPE 185
TABLE 113 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 114 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 186
TABLE 115 EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 116 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 117 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 188
TABLE 118 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 188
TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 189
TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
TABLE 121 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 190
11.3.1 EUROPE: RECESSION IMPACT 190
11.3.2 GERMANY 191
11.3.2.1 Germany to dominate European immunoassay market during forecast period 191
TABLE 122 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 192
TABLE 123 GERMANY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 124 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 125 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 193
TABLE 126 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194
TABLE 127 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 194
TABLE 128 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 129 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 196
11.3.3 ITALY 196
11.3.3.1 Growing geriatric population and increasing support for research to drive market 196
TABLE 130 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197
TABLE 131 ITALY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 132 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 133 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 198
TABLE 134 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 199
TABLE 135 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 199
TABLE 136 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200
TABLE 137 ITALY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 201
11.3.4 FRANCE 201
11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market 201
TABLE 138 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 202
TABLE 139 FRANCE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 140 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 141 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 203
TABLE 142 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 204
TABLE 143 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 204
TABLE 144 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 145 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 206
11.3.5 SPAIN 206
11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market 206
TABLE 146 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 207
TABLE 147 SPAIN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 148 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 149 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 208
TABLE 150 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 209
TABLE 151 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 209
TABLE 152 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 210
TABLE 153 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 211
11.3.6 UK 211
11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market 211
TABLE 154 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 212
TABLE 155 UK: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 156 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 157 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 214
TABLE 158 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 214
TABLE 159 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 215
TABLE 160 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 215
TABLE 161 UK: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 216
11.3.7 RUSSIA 216
11.3.7.1 Lack of reimbursement and delays in approval to limit market 216
TABLE 162 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 217
TABLE 163 RUSSIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 164 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 165 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 218
TABLE 166 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 219
TABLE 167 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 219
TABLE 168 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 220
TABLE 169 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 221
11.3.8 REST OF EUROPE 221
TABLE 170 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 222
TABLE 171 REST OF EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 172 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 173 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 223
TABLE 174 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 224
TABLE 175 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 224
TABLE 176 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 177 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 226
11.4 ASIA PACIFIC 226
FIGURE 35 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 227
TABLE 178 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 228
TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 228
TABLE 180 ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 181 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 230
TABLE 183 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 230
TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 231
TABLE 185 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 231
TABLE 186 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 232
11.4.1 ASIA PACIFIC: RECESSION IMPACT 232
11.4.2 JAPAN 232
11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market 232
TABLE 187 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 233
TABLE 188 JAPAN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 189 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 190 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 235
TABLE 191 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 235
TABLE 192 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 236
TABLE 193 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 236
TABLE 194 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 237
11.4.3 CHINA 237
11.4.3.1 Increasing government investment and rising geriatric population to drive market 237
TABLE 195 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 238
TABLE 196 CHINA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 197 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 198 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 240
TABLE 199 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 240
TABLE 200 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 241
TABLE 201 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 241
TABLE 202 CHINA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 242
11.4.4 INDIA 242
11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market 242
TABLE 203 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 243
TABLE 204 INDIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 205 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 206 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 245
TABLE 207 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 245
TABLE 208 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 246
TABLE 209 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 246
TABLE 210 INDIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 247
11.4.5 AUSTRALIA 247
11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market 247
TABLE 211 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 248
TABLE 212 AUSTRALIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 213 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 214 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 249
TABLE 215 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 250
TABLE 216 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 250
TABLE 217 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 251
TABLE 218 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 251
11.4.6 SOUTH KOREA 252
11.4.6.1 Rising healthcare spending and investments in research to drive market 252
TABLE 219 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 252
TABLE 220 SOUTH KOREA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 221 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 222 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 254
TABLE 223 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 254
TABLE 224 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 255
TABLE 225 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 255
TABLE 226 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 256
11.4.7 INDONESIA 256
11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market 256
TABLE 227 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 257
TABLE 228 INDONESIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 257
TABLE 229 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 230 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 258
TABLE 231 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 259
TABLE 232 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 259
TABLE 233 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 234 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 260
11.4.8 REST OF ASIA PACIFIC 261
TABLE 235 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 262
TABLE 236 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 237 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 238 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 263
TABLE 239 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 264
TABLE 240 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 264
TABLE 241 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 265
TABLE 242 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 266
11.5 LATIN AMERICA 266
TABLE 243 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 267
TABLE 244 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 267
TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 246 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 247 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 269
TABLE 248 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 269
TABLE 249 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 270
TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 270
TABLE 251 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 271
11.5.1 LATIN AMERICA: RECESSION IMPACT 271
11.5.2 BRAZIL 271
11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022 271
TABLE 252 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 272
TABLE 253 BRAZIL: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 254 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 255 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 274
TABLE 256 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 274
TABLE 257 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 275
TABLE 258 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 275
TABLE 259 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 276
11.5.3 MEXICO 276
11.5.3.1 Increasing geriatric population and rising medical tourism to drive market 276
TABLE 260 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 277
TABLE 261 MEXICO: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 262 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 263 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 278
TABLE 264 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 279
TABLE 265 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 279
TABLE 266 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 280
TABLE 267 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 280
11.5.4 REST OF LATIN AMERICA 281
TABLE 268 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 281
TABLE 269 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 282
TABLE 270 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 282
TABLE 271 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 283
TABLE 272 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 283
TABLE 273 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 284
TABLE 274 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 284
TABLE 275 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 285
11.6 MIDDLE EAST & AFRICA 285
11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH 285
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 286
TABLE 276 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 286
TABLE 277 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 286
TABLE 278 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 279 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION) 287
TABLE 280 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 288
TABLE 281 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 288
TABLE 282 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 289
TABLE 283 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 290
12 COMPETITIVE LANDSCAPE 291
12.1 OVERVIEW 291
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 291
12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 291
TABLE 284 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET 291
12.3 REVENUE ANALYSIS 292
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS 293
12.4 MARKET SHARE ANALYSIS 293
TABLE 285 DEGREE OF COMPETITION IN IMMUNOASSAY MARKET 294
FIGURE 37 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022) 294
12.5 COMPANY EVALUATION MATRIX 295
12.5.1 STARS 295
12.5.2 EMERGING LEADERS 295
12.5.3 PERVASIVE PLAYERS 295
12.5.4 PARTICIPANTS 295
FIGURE 38 COMPANY EVALUATION MATRIX, 2022 296
12.5.5 COMPANY FOOTPRINT 296
TABLE 286 OVERALL FOOTPRINT 296
TABLE 287 PRODUCT FOOTPRINT 297
TABLE 288 REGIONAL FOOTPRINT 298
12.6 START-UP/SME EVALUATION MATRIX 299
12.6.1 PROGRESSIVE COMPANIES 299
12.6.2 RESPONSIVE COMPANIES 299
12.6.3 DYNAMIC COMPANIES 299
12.6.4 STARTING BLOCKS 299
FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022 300
12.6.5 COMPETITIVE BENCHMARKING 301
TABLE 289 KEY START-UPS/SMES IN IMMUNOASSAY MARKET 301
12.7 COMPETITIVE SCENARIOS AND TRENDS 302
12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS 302
TABLE 290 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–SEPTEMBER 2023 302
12.7.2 KEY DEALS 303
TABLE 291 KEY DEALS, JANUARY 2020–SEPTEMBER 2023 303
12.7.3 OTHER KEY DEVELOPMENTS 304
TABLE 292 OTHER KEY DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2023 304
13 COMPANY PROFILES 305
13.1 KEY PLAYERS 305
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ABBOTT LABORATORIES 305
TABLE 293 ABBOTT LABORATORIES: COMPANY OVERVIEW 305
FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 306
13.1.2 F. HOFFMANN-LA ROCHE LTD. 310
TABLE 294 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 310
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 311
13.1.3 SIEMENS HEALTHINEERS AG 317
TABLE 295 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 317
FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 318
13.1.4 DANAHER CORPORATION 322
TABLE 296 DANAHER CORPORATION: COMPANY OVERVIEW 322
FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 323
13.1.5 THERMO FISHER SCIENTIFIC INC. 327
TABLE 297 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 327
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 328
13.1.6 REVVITY 332
TABLE 298 REVVITY: COMPANY OVERVIEW 332
FIGURE 45 REVVITY: COMPANY SNAPSHOT (2022) 332
13.1.7 BECTON, DICKINSON AND COMPANY 336
TABLE 299 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 336
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 337
13.1.8 DIASORIN S.P.A. 340
TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW 340
FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 341
13.1.9 BIO-RAD LABORATORIES, INC. 344
TABLE 301 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 344
FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 345
13.1.10 QUIDELORTHO CORPORATION 348
TABLE 302 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 348
FIGURE 49 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 349
13.1.11 BIOMÉRIEUX 355
TABLE 303 BIOMÉRIEUX: COMPANY OVERVIEW 355
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 356
13.1.12 QIAGEN N.V. 359
TABLE 304 QIAGEN N.V.: COMPANY OVERVIEW 359
FIGURE 51 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 360
13.1.13 SYSMEX CORPORATION 362
TABLE 305 SYSMEX CORPORATION: COMPANY OVERVIEW 362
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 363
13.1.14 AGILENT TECHNOLOGIES, INC. 366
TABLE 306 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 366
FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 367
13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 369
TABLE 307 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 369
FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022) 369
13.2 OTHER PLAYERS 371
13.2.1 MERCK KGAA 371
13.2.2 MERIDIAN BIOSCIENCE 372
13.2.3 BIO-TECHNE 373
13.2.4 CELLABS 374
13.2.5 ABNOVA CORPORATION 375
13.2.6 J. MITRA & CO. PVT. LTD. 375
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCE) 376
13.2.8 CELL SCIENCES 376
13.2.9 ENZO BIOCHEM 377
13.2.10 CREATIVE DIAGNOSTICS 378
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY 378
13.2.12 ELABSCIENCE 379
13.2.13 WAK-CHEMIE MEDICAL 379
13.2.14 SERACARE LIFESCIENCES INC. 380
13.2.15 EPITOPE DIAGNOSTICS 380
13.2.16 KAMIYA BIOMEDICAL COMPANY 381
13.2.17 GYROS PROTEIN TECHNOLOGIES 381
13.2.18 TRIVITRON HEALTHCARE 382
13.2.19 INBIOS INTERNATIONAL, INC. 382
13.2.20 MACCURA BIOTECHNOLOGY CO., LTD. 383
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 384
14.1 DISCUSSION GUIDE 384
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 389
14.3 CUSTOMIZATION OPTIONS 391
14.4 RELATED REPORTS 391
14.5 AUTHOR DETAILS 394
